Generated by AI
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection. Eledon is currently advancing research programs in kidney transplantation, islet cell transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Its work centers on therapies intended to protect transplanted organs, reduce rejection risk, and address serious diseases with limited treatment options. Headquartered in Irvine, California, Eledon Pharmaceuticals operates as a focused drug development company within the broader biotechnology and immunology market.
Website19800 MacArthur Boulevard
Irvine, CA, 92612
United States
The latest articles about ELDN.
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treate...
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the presentation are b
Summary of Nov 16's posts. Generated by AI.
Summary of Jun 22's posts. Generated by AI.
Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.
Summary of Nov 19's posts. Generated by AI.
Investors talking about ELDN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.